Tandem Diabetes Care (NASDAQ:TNDM) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS

Key Points

• Tandem beat Q1 expectations with ($0.30) EPS vs. ($0.46) consensus and revenue of $247.2M (up 5.5% YoY); management reaffirmed 2026 guidance while Q1 non‑GAAP gross margin reached a record 55% and the company finished the quarter with about $570M in cash.
• Operationally the firm reported >29,000 pump shipments, began its PayGo pharmacy rollout (~40% early formulary coverage) and advanced product milestones (Android support for Mobi, Control‑IQ+ cleared for pregnancy), but infusion‑set supplier shortages are causing supply pressure and a roughly $3–$4M timing headwind into Q2.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) issued its earnings results on Thursday. The medical device company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.16, FiscalAI reports. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 68.23%. The business had revenue of $247.22 million for the quarter, compared to the consensus estimate of $240.41 million. During the same quarter in the previous year, the firm earned ($0.66) earnings per share. The business's quarterly revenue was up 5.5% compared to the same quarter last year.

Here are the key takeaways from Tandem Diabetes Care's conference call:

• Tandem reported strong Q1 results with more than 29,000 pump shipments and $247 million in sales, and management is reaffirming 2026 guidance.
• The company has begun its PayGo pharmacy rollout, achieving ~40% formulary coverage early and <5% initial pharmacy ordering, a strategic shift management says will raise ASPs and margins as execution scales.
• Product momentum accelerated: Mobi now supports Android in the U.S., Control‑IQ+ cleared for use in pregnancy (first AID cleared for pregnancy in the U.S.), Libre 3 Plus and Dexcom G7 integrations planned, international Mobi launch in Q2, and a Mobi Tubeless 510(k) filing and a pivotal fully closed‑loop study are on track.
• Infusion set supplier shortages created modest supply‑sales pressure and meaningful customer impact for affected SKUs, with the company expecting disruption to persist into Q2 and some $3M–$4M timing headwinds from the international go‑direct transition.
• Margins and balance sheet strengthened: Q1 non‑GAAP gross margin was 55% (a Q1 record), adjusted EBITDA improved, the company generated $5M free cash flow and ended the quarter with $570M in cash (including $276M net proceeds from convertible debt), supporting execution of strategy.

Tandem Diabetes Care Price Performance

NASDAQ TNDM traded up $0.44 during mid-day trading on Thursday, hitting $18.47. The stock had a trading volume of 2,622,228 shares, compared to its average volume of 1,653,314. The company has a 50 day simple moving average of $21.32 and a 200 day simple moving average of $20.33. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -6.02 and a beta of 1.64. Tandem Diabetes Care has a 52-week low of $9.98 and a 52-week high of $29.65. The company has a quick ratio of 2.02, a current ratio of 2.55 and a debt-to-equity ratio of 2.00.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Royal Bank of Canada grew its stake in Tandem Diabetes Care by 30.5% in the 1st quarter. Royal Bank of Canada now owns 211,666 shares of the medical device company's stock valued at $4,054,000 after acquiring an additional 49,408 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Tandem Diabetes Care by 2.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,413 shares of the medical device company's stock valued at $1,426,000 after purchasing an additional 2,096 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Tandem Diabetes Care by 41.1% in the first quarter. Millennium Management LLC now owns 227,585 shares of the medical device company's stock valued at $4,361,000 after purchasing an additional 66,245 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Tandem Diabetes Care in the first quarter valued at approximately $225,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of Tandem Diabetes Care by 5.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 712,559 shares of the medical device company's stock worth $13,653,000 after purchasing an additional 34,069 shares in the last quarter.

Wall Street Analysts Forecast Growth

TNDM has been the subject of a number of recent analyst reports. Piper Sandler upgraded shares of Tandem Diabetes Care from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $21.00 to $33.00 in a research report on Tuesday, March 17th. UBS Group reissued a "neutral" rating and issued a $22.00 price target (up from $17.00) on shares of Tandem Diabetes Care in a report on Friday, February 20th. Mizuho set a $22.00 price target on Tandem Diabetes Care and gave the company a "neutral" rating in a research note on Friday, February 20th. Stifel Nicolaus upped their price objective on Tandem Diabetes Care from $20.00 to $22.00 and gave the stock a "hold" rating in a report on Friday, February 20th. Finally, Lake Street Capital raised Tandem Diabetes Care from a "hold" rating to a "buy" rating and set a $50.00 target price for the company in a report on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Tandem Diabetes Care currently has a consensus rating of "Moderate Buy" and an average target price of $30.05.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc NASDAQ: TNDM, headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company's flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.